Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer

Authors :: Gregory B. Lesinski
Shannon Loftus
Thomas Ludwig
Reena Shakya
Mark Bloomston
Michael C. Ostrowski
Jason R. Pitarresi
Thomas A. Mace
Teresa A. Zimmers
Tanios Bekaii-Saab
Benjamin Swanson
Gregory S. Young
Xioling Zhong
Source :: Journal for Immunotherapy of Cancer
Publisher :: Springer Nature
Abstract: Meeting abstracts Checkpoint inhibition has gained traction as an immunotherapeutic approach. However, limited efficacy has been observed in patients with pancreatic ductal adenocarcinoma (PDAC). Prior studies by our group have indicated that human pancreatic stellate cells (PSC), a major component

Full Text Access

Tools